Showing results (241-250 of 364) with videos related to
Sort By:
Pageof 37
Journal of the American Academy of Dermatology|May 6, 2021
Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studiesKim Papp, Jacek C Szepietowski, Leon Kircik, et al.Journal of Dentistry for Children (Chicago, Ill.)|December 20, 2023
Ohio School Nurses´ Perceptions of School Absences for Dental CareJanice Townsend, Jin Peng, Jodee McDaniel, et al.The British Journal of Dermatology|April 20, 2022
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): a clinical outcome measure for the severity of atopic dermatitisEric L Simpson, Robert Bissonnette, Amy S Paller, et al.Journal of Drugs in Dermatology : JDD|December 4, 2024
Triple-Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Moderate-to-Severe Acne in Children and AdolescentsLawrence F Eichenfield, Adelaide A Hebert, Julie C Harper, et al.Pediatric Dermatology|November 12, 2024
Low Infection Rates With Long-Term Dupilumab Treatment in Patients Aged 6 Months to 5 Years: An Open-Label Extension StudyAmy S Paller, Michele Ramien, Michael J Cork, et al.Pediatric Dermatology|September 27, 2020
Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild-to-moderate atopic dermatitisLawrence F Eichenfield, Gil Yosipovitch, Linda F Stein Gold, et al.JAMA Dermatology|August 18, 2021
Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical TrialLawrence F Eichenfield, Carsten Flohr, Robert Sidbury, et al.Journal of the American Academy of Dermatology|May 7, 2023
Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand: A cross sectional study from the TARGET-DERM AD cohortJonathan I Silverberg, Brenda Simpson, Katrina Abuabara, et al.Journal of the American Academy of Dermatology|January 22, 2018
Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)Eric L Simpson, Carsten Flohr, Lawrence F Eichenfield, et al.American Journal of Clinical Dermatology|September 1, 2018
Major Comorbidities of Atopic Dermatitis: Beyond Allergic DisordersAmy Paller, Jennifer C Jaworski, Eric L Simpson, et al.Pageof 37